^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Solid Tumor
    Drug:erfonrilimab (KN046) (PD-L1 inhibitor, CTLA4 inhibitor) +
    anbenitamab (KN026) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

    Excerpt:
    ...Cohorts A and B: Histologically confirmed unresectable HER2-positive metastatic colorectal cancer, meeting the following criteria: a) Previously untreated with systemic anti-tumor therapy, or the time from (neo)adjuvant chemotherapy completion to disease recurrence > 6 months; b) Gene sequencing shows wild-type RAS and BRAF (participants' previous KRAS and BRAF test results are acceptable)....
    Trial ID:
    HERCKER-01
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

    Excerpt:
    ...- Histologically or cytologically confirmed, metastatic or locally advanced unresectable HER2-positive solid tumors;...
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

    Excerpt:
    ...- Histologically or cytologically documented advanced HER2 positive solid tumor...
    Trial ID:
    NCT04040699
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

    Excerpt:
    ...- Histologically or cytologically confirmed, locally advanced HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma....
    Trial ID:
    NCT06023758
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.

    Published date:
    05/23/2023
    Excerpt:
    KN026 combined with KN046 treatment had demonstrated favorable efficacy and safety profile in HER2 positive other solid tumors (non-GC/GEJ and non-BC).
    DOI:
    10.1200/JCO.2023.41.16_suppl.3621
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SITC 2020
    Title:

    339 Preliminary safety, tolerability and efficacy results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in patients (pts) with HER2 aberrated solid tumors

    Published date:
    11/09/2020
    Excerpt:
    Eligible pts received combination of KN026 and KN046...The objective response rate in pts with HER2-positive tumors (n = 7 efficacy evaluable pts) was 4/7 (57.1%, 95% CI 18.4~90.1%) and disease control rate 6/7 (85.7%, 95% CI 42.1~99.6%)….KN026 combined with KN046 is well tolerated and has demonstrated profound anti-tumor activity in HER2-positive solid tumors.
    DOI:
    10.1136/jitc-2020-SITC2020.0339
    Trial ID:
    NCT04040699
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SITC 2020
    Title:

    810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors

    Published date:
    11/09/2020
    Excerpt:
    KN026 combined with KN046 is well tolerated and has demonstrated preliminary albeit profound anti-tumor activity in HER2-positive solid tumors.
    DOI:
    10.1136/jitc-2020-SITC2020.0810